Economics Faculty Publications

Economics

2-24-2020

Congenital Chagas Disease in the United States: The Effect of
Commercially Priced Benznidazole on Costs and Benefits of
Maternal Screening
Victoria Perez-Zetune
University Of Maryland College Park

Stephanie R. Bialek
Centers for Disease Control and Prevention

Susan P. Montgomery
Centers for Disease Control and Prevention

Eileen Stillwaggon
Gettysburg College

Follow this and additional works at: https://cupola.gettysburg.edu/econfac
Part of the Health Economics Commons, and the Maternal and Child Health Commons

Share feedback about the accessibility of this item.
Recommended Citation
Perez-Zetune, V., Montgomery, S., Bialek, S., Stillwaggon, E. (2020). Congenital Chagas disease in the
United States: the effect of commercially priced benznidazole on costs and benefits of maternal
screening. American Journal of Tropical Medicine and Hygiene, 102(5), 1086‒1089.

This open access article is brought to you by The Cupola: Scholarship at Gettysburg College. It has been accepted
for inclusion by an authorized administrator of The Cupola. For more information, please contact
cupola@gettysburg.edu.

Congenital Chagas Disease in the United States: The Effect of Commercially
Priced Benznidazole on Costs and Benefits of Maternal Screening
Abstract
Chagas disease, caused by Trypanosoma cruzi, is transmitted by insect vectors, and through
transfusions, transplants, insect feces in food, and mother to child during gestation. An estimated 30% of
infected persons will develop lifelong, potentially fatal cardiac or digestive complications. Treatment of
infants with benznidazole is highly efficacious in eliminating infection. This work evaluates the costs of
maternal screening and infant testing and treatment for Chagas disease in the United States, including
the cost of commercially available benznidazole. We compare costs of testing and treatment for mothers
and infants with the lifetime societal costs without testing and consequent morbidity and mortality due to
lack of treatment or late treatment. We constructed a decision-analytic model, using one tree that shows
the combined costs for every possible mother–child pairing. Savings per birth in a targeted screening
program are $1,314, and with universal screening, $105 per birth. At current screening costs, universal
screening results in $420 million in lifetime savings per birth-year cohort. We found that a congenital
Chagas screening program in the United States is cost saving for all rates of congenital transmission
greater than 0.001% and all levels of maternal prevalence greater than 0.06% compared with no screening
program.
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Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole
on Costs and Beneﬁts of Maternal Screening
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Abstract. Chagas disease, caused by Trypanosoma cruzi, is transmitted by insect vectors, and through transfusions,
transplants, insect feces in food, and mother to child during gestation. An estimated 30% of infected persons will develop
lifelong, potentially fatal cardiac or digestive complications. Treatment of infants with benznidazole is highly efﬁcacious in
eliminating infection. This work evaluates the costs of maternal screening and infant testing and treatment for Chagas
disease in the United States, including the cost of commercially available benznidazole. We compare costs of testing and
treatment for mothers and infants with the lifetime societal costs without testing and consequent morbidity and mortality
due to lack of treatment or late treatment. We constructed a decision-analytic model, using one tree that shows the
combined costs for every possible mother–child pairing. Savings per birth in a targeted screening program are $1,314,
and with universal screening, $105 per birth. At current screening costs, universal screening results in $420 million in
lifetime savings per birth-year cohort. We found that a congenital Chagas screening program in the United States is cost
saving for all rates of congenital transmission greater than 0.001% and all levels of maternal prevalence greater than
0.06% compared with no screening program.

areas and blood screening, congenital transmission accounts
for an increasing share (1/4) of new cases, with approximately
9,000 congenital infections per year in Latin America and
several hundred in the United States and Europe.4,5,8 An estimated 30% of infected persons will develop lifelong, potentially fatal cardiac or digestive complications.9,10
Efﬁcacy of benznidazole treatment for infants younger than
1year is 90–100%, and for adults, efﬁcacy ranges from 40% to
70% depending on age and length of time since infection.8,11
Moreover, the risk of congenital transmission is considerably
lower for women treated before pregnancy.12,13 For infected
persons with chronic conditions, treatment has not been found
to remediate existing cardiac or digestive tract damage.14 A 2018
retrospective study, however, found substantial beneﬁts for
persons with chronic Chagas disease who were treated, primarily before the age of 40 years. Compared with persons never
treated with benznidazole, the treatment group had an odds ratio
of 0.21 for mortality within 2 years, of 0.23 for electrocardiogram
(ECG) abnormalities, and of 0.27 for T. cruzi DNA on polymerase
chain reaction (PCR).15
The CDC provided benznidazole treatment at no cost for
369 patients from 2011 to 2018 in 41 states and the District of
Columbia.2 Patient enrollment in the CDC program ended in
May 2018 when Exeltis USA, Inc. (Florham Park, NJ) began
commercial supply of benznidazole. Exeltis is a subsidiary of
Insud Pharma, which runs a nonproﬁt foundation, Mundo
Sano. Between May 2018 and January 2019, 85 patients with
suspected T. cruzi infection were treated in 19 states
(Exeltis).
To date, there is no maternal screening policy for Chagas
disease in the United States. Food and Drug Administration
approval of benznidazole for treatment of infants is pending
(Exeltis). Early diagnosis could prevent severe and even
deadly complications associated with the chronic stage of the
disease in infants and their mothers. Pregnant women are the
best access point for diagnosing and treating entire families
because delivery is the most likely time for contact with the
healthcare system. In 2017, Hispanics had the highest

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, can cause serious, even fatal, cardiac and gastrointestinal damage in 30% of persons infected. Maternal transmission
is becoming an increasingly important share of new infections as
the success of other control measures continues. Benznidazole is
highly effective in treating infants and effective in treating adolescents and young adults. Previously, we demonstrated that a universal program of screening and treating infants and mothers would
be cost saving. Benznidazole is now approved by the Food and
Drug Administration (FDA) and is commercially available. We
demonstrate that a universal screening and treatment program is
still cost saving in the United States, even with commercially priced
benznidazole.
In August 2017, the US FDA approved benznidazole, one of
two drugs used to treat Chagas disease, for treatment of
children ages 2–12 years and by physician discretion outside
that age range.1 Benznidazole became commercially available
on May 14, 2018.2 In the June 2018 issue (Vol. 98, No. 6) of this
journal (available online April 30, 2018),3 we published an
economic decision-analytic model evaluating the societal
cost of universal screening of pregnant women for Chagas
disease in the United States. This report incorporates the
commercial cost of treatment with benznidazole into our
model of the economic costs and beneﬁts of maternal
screening and treatment for mother–child pairs.
Chagas disease is caused by T. cruzi transmitted by triatomine insects found in Central and South America, Mexico,
and the southern United States.4 An estimated 5.7 million
people in Latin America are infected with T. cruzi, with an
additional 400,000 Latin Americans abroad, primarily in the
United States (about 300,000), Spain, and Japan.5–7 Chagas
disease is also spread by blood transfusions, organ transplants, consumption of insect feces in food, and congenital
transmission. Because of success in vector control in endemic
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TABLE 1
Key parameters
Parameter

Name in tree

Point estimate (range)

Sources

Prevalence
Mother-to-child transmission rate
Benznidazole, infant
Benznidazole, mother
Testing cost, infant
Testing cost, mother

Prevalence
MTCT
Rx_baby
Rx_mom
Dx_baby
Dx_mom

0.0131 (0.0–0.0131)
0.05 (0.0–0.05)
$180
$720
$400
$60 ($8–$60)

Ref. 5 (ref. 29,30,32)
Ref. 6,33,34 (ref. 28,32,35–37)
Ref. 1,24
Ref. 1,24
Ref. 3
Table 2, multiple sources in ref. 3 (ref. 20)

uninsured rate, 16%, and the lowest rate of private insurance
coverage, 53.5%,16,17 and 30% of Hispanic adults reported
having no usual source of health care, the highest for any
group.18 Hispanic women, on the other hand, have the lowest
rate of out-of-hospital births of any group in the United States,
0.05%.19
Using a societal perspective, we compare the costs of
maternal screening and infant testing and treatment as
needed (the screening option) with the costs of no screening,
with its consequent morbidity and mortality due to lack of
treatment or late treatment. We constructed a decisionanalytic model for the United States using TreeAge software
(TreeAge Software Inc., Williamstown, MA) to ﬁnd the lower
cost option. As before, we use one tree that comprises a decision node (screening or no screening), chance nodes
(probabilities of maternal infection, transmission, and various
degrees of injury), and terminal nodes that correspond to each
possible mother–child outcome. Each outcome represents
the expected value of all economic costs based on a series of
conditional probabilities for each branch.3
Table 1 lists some key parameters for the model. Point estimates and ranges are derived from the literature indicated
in the source column. Full description of methods and data
sources appears in the original article and its online supplement.3 Although there have been new studies of Chagas
disease since 2018, none presents new data that would
change the model parameters, except the cost of benznidazole.
The point estimate for screening cost is $60 per pregnancy,
but the model also calculates for screening cost as low as $8
per pregnancy through sensitivity analysis. A new point-ofcare diagnostic test was approved by the FDA in December
2016 for which the expected price will be $4.00 ($8 with
conﬁrmatory test).20,21 We list a higher cost for infant PCR than
is in effect to maintain the conservative assumptions of the
earlier article. Currently, Chagas disease PCR testing is only
available at the CDC at no charge. Newborns should be tested
at birth and 4–6 weeks of age.22 To ensure that no infection is

missed by PCR testing, infants who were PCR negative at
both intervals should have serologic testing for antibody to
T. cruzi at the age of 9–10 months, after maternal antibody is
no longer present.22 The cost saving from a maternal
screening program could be especially sensitive to two
clinical variables: prevalence among pregnant women and
mother-to-child transmission risk. For both prevalence and
maternal transmission, we set zero as the lower bound
(Table 1).
Cost-to-charge ratios vary in the United States by state, by
provider, and by coverage. Exeltis provides benznidazole at a
variety of prices (charges), depending on whether the patient
has no insurance, inadequate insurance, or Medicare/Medicaid
coverage. A collaboration of Insud Pharma, Drugs for Neglected Diseases initiative, and Mundo Sano arranged the subsidization of pricing.23 Mundo Sano covers the gap so that no
patient faces exorbitant costs. For benznidazole, the average
Medicare patient full cost is $401, but patient out-of-pocket
costs are $34.24 Because pharmaceutical pricing in the United
States is essentially unrelated to economic cost, we do not use
Exeltis charges, but rather the Wholesale Acquisition Cost
(WAC). For a full 60-day course of treatment for an infant, the
cost is $180, and for the mother, $720.1,24
We found that commercial provision of benznidazole made
little difference in the cost savings derived from maternal
screening for Chagas disease. The savings per birth in a
targeted screening program, using prevalence of 0.0131
among Hispanic women from endemic areas, is $1,314, only
$10 less than with free benznidazole. We found that a program of universal screening would save $105 per birth,
compared with $106 per birth with free benznidazole.3 The
lower bound maternal prevalence of Chagas disease for
screening to be cost saving is 0.06%. The estimated prevalence of Chagas in US women of childbearing age is 0.16%.
The results are robust to variations in the rate of mother-tochild transmission down to 0.001%. Table 2 displays these
results.

TABLE 2
Results: lifetime societal costs and savings, no screening, and screening
$60 screening cost per birth
Scenario

Per birth

Per birth-year cohort

Targeted screening, 480,000 births, maternal prevalence of 1.31%
No screening
$2,321
$1,114,080,000
Screening
$1,007
$483,360,000
Savings
$1,314
$630,720,000
Universal screening, 4,000,000 births, maternal prevalence of 0.16%
No screening
$279
$1,116,000,000
Screening
$174
$696,000,000
Savings
$105
$420,000,000

$8 screening cost per birth
Per birth

Per birth-year cohort

$2,321
$955
$1,366

$1,114,080,000
$453,600,000
$660,480,000

$279
$121
$158

$1,116,000,000
$484,000,000
$632,000,000
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TABLE 3
Lifetime savings per birth cohort, implementation costs (screening, enhanced care, and benznidazole treatment), and beneﬁt–cost ratios
Targeted (480,000 births)

Lifetime savings per birth cohort
Screening cost
Enhanced care under screening
Cost of benznidazole
Total implementation costs
Beneﬁt–cost ratio

Universal (4 million births)

At $60 per screen

At $8 per screen

At $60 per screen

At $8 per screen

$630,270,000
$31,320,000
$31,528,000
$4,592,700
$67,440,700
9.35

$660,480,000
$6,360,000
$31,528,000
$4,592,700
$42,480,700
15.5

$420,000,000
$202,520,000
$31,528,000
$4,592,700
$278,640,700
1.5

$632,000,000
$34,520,000
$31,528,000
$4,592,700
$70,640,700
8.9

For screening with two point-of-care tests at $8, the savings
per birth is $1,366 in a targeted screening program and $158
per birth with universal screening. With the $8 screening cost,
the threshold for screening as the cost-saving option is maternal prevalence of 0.0000757 (0.008%). It is a construct of
the decision-tree method that the per-birth savings differ
substantially between targeted and universal screening. That
is because the per-birth savings are multiplied in each option
by the number of births, and the total savings are enormous
even in a universal program (Table 2).
Both targeted screening and universal screening are cost
saving over a wide range of prevalence and screening costs in
the United States. The only parameter that makes an important difference in the amount of savings from the screening
option is maternal prevalence. Varying mother-to-child
transmission from 0.0 to 0.05 has a trivial effect on the estimate of savings. Thus, even if maternal transmission is extremely low in the United States because of environmental or
biological factors, that makes little difference in the large
savings from screening. Including the cost of a second infant
PCR makes a trivial difference in the result.
Implementation of universal screening with a point-of-care
test would cost $70.6 million, including screening cost,
benznidazole treatment for mothers and babies, and costs of
enhanced care for women with digestive conditions or indeterminate status who would not have been identiﬁed in the
no-screening scenario. The beneﬁt ($632 million, the discounted present value of the savings) is almost nine times the
cost of the screening program for each birth-year cohort
(Table 3).
Targeted screening toward ﬁrst- and second-generation
Latinas from endemic areas could be less costly, but surveys
of obstetricians indicate a lack of information about Chagas
disease.22,25 Because the Hispanic population is distributed
across the United States,26 incorporating T. cruzi into routine
screening may be more feasible. The US political climate
makes it risky for many Hispanics to seek medical attention;27
universal screening avoids proﬁling and is likely to be more
acceptable to vulnerable women. Pregnant women and
newborns are already screened for a wide variety of genetic
conditions and congenitally transmitted diseases, including
syphilis, HIV, and, in some states, toxoplasmosis, rubella,
and cytomegalovirus.28–30 Our model demonstrates that,
even at current testing costs, maternal screening and followup infant testing and treatment as needed are cost saving for
maternal prevalence as low as 0.057% and for mother-tochild transmission probability as low as 0.001%. With the
new point-of-care test, universal screening is cost saving
for prevalence as low as 0.008% of pregnant women. Lifetime societal costs, including direct medical costs and

productivity loss due to morbidity and premature mortality,
are 8.9 times the cost of implementing a universal maternal
screening program. This analysis supports adding testing for
T. cruzi infection to routine screening in pregnancy or at the
time of delivery.
The analysis could have limited application in other countries if subsidized pricing of benznidazole was not available.
On the other hand, US pharmaceutical prices are the highest in
the world.31 A second limitation is the high cost attributed to
infant PCR, but a more realistic cost (currently zero) would only
increase the estimated savings.
Screening and preventive programs in general are often
assumed to be very expensive, especially for low-prevalence
conditions. As this study demonstrates, the lifetime costs of
morbidity and mortality for infected mothers and babies far
outweigh the implementation costs. Moreover, positive serology indicates the need to test the mother’s older children,
as well as the newborn, increasing the beneﬁts. After maternal
treatment, subsequent pregnancies would be protected from
transmission.12,13 Given the outstanding beneﬁts in the earlier
study,3 it is not surprising that the beneﬁts remain even with
commercially available benznidazole. Moreover, the drug
provider has guaranteed affordable pricing, and relatively few
mothers and babies need to be treated. Screening cost, even
at present, is low, and it is likely to be much lower in the near
future. Logistically, universal screening is preferable to targeted screening and is still cost saving.
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